MIAMI–(BUSINESS WIRE)–Ambulero, Inc. is developing a first-in-class gene and cell therapy platform for treating serious vascular diseases and non-healing wounds where amputation is a care option. In support of this effort, the NHLBI CATALYZE program of the National Institutes of Health approved a second phase of funding for IND-enabling work […]